An eight-week, double-blind placebo controlled, multicenter study evaluating the efficacy, safety, tolerability of a fixed dose of SR58611A [amibegron] (350 mg q12) in elderly patients with major depressive disorder (MDD).

Trial Profile

An eight-week, double-blind placebo controlled, multicenter study evaluating the efficacy, safety, tolerability of a fixed dose of SR58611A [amibegron] (350 mg q12) in elderly patients with major depressive disorder (MDD).

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Amibegron (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms ZEPHIR
  • Sponsors Sanofi
  • Most Recent Events

    • 12 Jul 2011 Additional trial location (France) added as reported by European Clinical Trials Database.
    • 12 Jul 2011 New source added and integrated (European Clinical Trials Database, EudraCT2005-005597-67).
    • 13 Nov 2008 End dates added, identifier added.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top